About Epitomics
Epitomics is a company based in Burlingame (United States) founded in 2001 by Weimin Zhu and Guo Liang Yu was acquired by Abcam in March 2012. Epitomics has raised $16.21 million across 3 funding rounds from investors including Abcam, Sycamore Ventures and Amkey Ventures. Epitomics offers products and services including Primary Antibodies, ELISA Kits, and Cell Lines. Epitomics operates in a competitive market with competitors including GenScript, Sino Biological, Y-Biologics, Mabtech and Shanghai OPM Biosciences, among others.
- Headquarter Burlingame, United States
- Founders Weimin Zhu, Guo Liang Yu
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abcam Limited
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Epitomics
Epitomics offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, and Cell Lines.
High-specificity antibodies for detecting proteins in experiments.
Kits for sensitive immunoassay detection of various targets.
Validated cell lines for gene-editing and research applications.
Funding Insights of Epitomics
Epitomics has successfully raised a total of $16.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $2.11 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Epitomics
Epitomics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Abcam, Sycamore Ventures and Amkey Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Epitomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Epitomics
Investment portfolio details for Epitomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Epitomics
Detailed financials for Epitomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epitomics Comparisons
Peer comparison for Epitomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Epitomics
Epitomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenScript, Sino Biological, Y-Biologics, Mabtech and Shanghai OPM Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Developer of antibodies for the treatment of multiple diseases
|
|
| Locked | Locked | Locked |
Antibodies and immunoassay kits are developed for research applications.
|
|
| Locked | Locked | Locked |
Antibody and vaccine culture media products are developed.
|
Detailed competitors of Epitomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epitomics
Complete news archive for Epitomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epitomics
Epitomics was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Epitomics is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.
Guo Liang Yu is the current CEO of Epitomics. They have also founded this company.
Epitomics is a funded company, having raised a total of $16.21M across 3 funding rounds to date.
Epitomics is a biotechnology focussed on developing MAb technology and products. It developed rabbit MAb technology RabMAb for the creation of specific and custom rabbit MAbs that has potential in new MAb therapies. It claims that the MAbs produced from the technology acted as challenging targets such as splice variants, point mutations, species-specific orthologs, post-translational modifications, and small molecule compounds and has benefitted more than 550 institutions and 150 pharma and biotech companies. In March 2012, Abcam acquired Epitomics and since then working as its subsidiary.
Epitomics's top competitors include Sino Biological, GenScript and Y-Biologics.
Epitomics offers Primary Antibodies, ELISA Kits, and Cell Lines.
Epitomics has 4 investors. Key investors include Abcam, Sycamore Ventures, Amkey Ventures, and Kenson Ventures.